Research Reports

Panache Beverage, Inc. (OTCQB – WDKA)

InvestorsInsight.com — Fri, 12 Apr 2013 15:17:41 GMT

Panache is an alcoholic beverage company specializing in the development, global sales and marketing of spirits brands. Panache is following a unique “build and exit” business model. Existing portfolio contains three brands: Wodka Vodka, Alchemia Vodka and Alibi Whiskey.

Investment Highlights:

$10 million backlog for “Alibi American Whiskey” announced in December 2012 – exclusive two year national distribution agreement with Domaine Select Wine Estates, LLC
Major spirits companies have largely abandoned grassroots developments of brands - now favor an “acquire to grow” philosophy
Panache’s niche is “build and exit” - development and global sales and marketing of unique spirits brands for acquisition
Panache became import company of record for premium vodka 42 BELOW in late 2004 - Bacardi purchased the brand for $91 million two years later (representing a gain on sale of $71 million)
$970 Billion Global Alcoholic Beverage Market – US is most important liquor market in the world, and this management team knows how to exploit it for maximum shareholder value

30-page Research Report Details Unique Business Model, Industry, Valuation... plus Income Statement and Financial Projections thru 2016.

EnerJex Resources, Inc. (ENRJ - OTCQB)

InvestorsInsight.com — Thu, 28 Mar 2013 05:54:12 GMT

EnerJex is an E&P company with producing assets located in Eastern Kansas and South Texas. The Company is focused on the acquisition and development of shallow oil properties that have low production decline rates and offer abundant drilling opportunities with low risk profiles.

Investment Highlights:

Achieved 97.6% Drilling Success Rate - drilled 123 economically successful oil wells out of 126 wells drilled in its Kansas plays.
Hundreds of Low-Risk Shallow Oil Drilling Opportunities Identified on Existing Properties - cash on cash IRR's on these wells often approaches or exceeds 50%.
Shares currently trading at 50% discount to market value - ENRJ closed at $0.60 per share on Monday 4/1/2013. Market value projected to be $1.21.

29-page Research Report Details Current Market Valuation... leasehold positions, plus Income Statement and Financial Projections thru 2016.

Eco Ventures Group, Inc. (EVGI – OTCQB)

InvestorsInsight.com — Sun, 18 Nov 2012 01:03:13 GMT

EVGI Has Option to Acquire 100% of Rapidly Growing German Energiepark Süptitz, GmbH, and is Near Completion of Its Florida Biodiesel Production Facility. Biofuels Market is Strong Worldwide, Providing Likely Future Margin Improvements. Strong Speculative Buy.

Vycor Medical (VYCO)

InvestorsInsight.com — Mon, 17 Sep 2012 15:48:25 GMT

Vycor Medical Has Breakthrough Product Offerings in the Neurosurgical and Stroke-Related Vision Rehabilitation Markets. We Expect Strong Sales Growth in Late 2012 and 2013, and See Sustainable Hyper-growth Potential in 2014 and Beyond. Strong Buy.

Information Systems Associates, Inc. (IOSA) - WSR Equity Research Report

InvestorsInsight.com — Wed, 08 Jun 2011 16:14:10 GMT

Data centers are the backbone of technology, storing massive amounts of data. Until recently, data centers were viewed as a necessary evil without much regard to their efficiency or ability to contribute to an organization’s profitability. However, the concept of DCIM is changing that perception, which is putting the DCIM sector into hyperdrive. Over the next decade, the DCIM market is expected to grow from $150 million to over $7.5 billion in revenue. Why is this important for Information Systems Associates?

ISA’s OPSI system is the only patent-protected mobile data center device that enables a data center manager to account for changes in the data center remotely. More importantly, ISA is evolving its patented OSPI system into a real-time DCIM mobile management tool empowering the data center manager to make critical IT changes by transmitting data to and from the data center by using a computer or even a smartphone. ISA has the proprietary technological solution that will help launch this nascent market into the multi-billion growth engine that will help to redesign how data centers work in the future. This is a game-changer in the industry. In addition to its ground-breaking technology, it also has a highly experienced management team that is primarily compensated with equity in shares of IOSA. Management has strong sales/marketing and product development skills with a proven track record--growing Rackwise from a small data center productivity company with a $2,000 product, to a large top tier DCIM software company with a multi hundred thousand dollar product.

Davi Luxury Brand Group, Inc. (MDAV) - EquityNet Research Report

InvestorsInsight.com — Wed, 23 Feb 2011 02:31:33 GMT

Davi Luxury Brand Group, Inc., develops, licenses and markets luxury skincare products founded by Carlo Mondavi, grandson of American winemaking icon Robert Mondavi, using the powerful, natural antioxidants found in wine and grapes. The Company markets its skincare products under the “DAVI Skin” and DAVI” brand names. The Company’s own Antioxidant Meritage Complex is designed to efficiently and effectively deliver the healing benefits of superior product ingredients directly to the skin.

Through special planting techniques at select vineyards, the grapes grown at these vineyards yield higher concentrations of minerals, vitamins, and nutrients than grapes from traditional winemaking vineyards. The minerals, vitamins and nutrients are found in a by-product of the wine making process called the pomace, which yields polyphenols in relatively high quantity. Polyphenols are the free radical scavengers that, among other things, help to protect collagen and elastin fibers and prevent the destruction of hyaluronic acid in the skin. Management believes that the use of this pomace will allow for the creation of skin crèmes that can help fight the natural aging process of the skin.

WebSafety, Inc. (WBSI - OTC:BB) - Coverage Initiation Report by Harbinger Research

InvestorsInsight.com — Tue, 11 Jan 2011 23:44:48 GMT

WebSafety seems to be in the right place at the right time. They have an innovative software solution to a very real set of problems, namely distracted driver accidents and online abuse of and predation on children. Furthermore, the public is in the initial phases of becoming aware of these risks and the need to combat them, which should greatly assist the Company in gaining broad market traction. Like any small, young company, WebSafety has its challenges, and we do not expect its path to the status of a market leader to be a cakewalk. However, we see such large potential in the Company’s business plan, product offering, and initial online sales/marketing success that despite the risks we nevertheless view an investment in WebSafety very positively. While we are not setting a price target or revenue/earnings estimates at this time, we do recommend purchase of WBSI shares for risk-tolerant investors who are seeking a large potential future return.

Bohai Pharmaceuticals Group, Inc. (BOPH) - Murphy Analytics Coverage Update

InvestorsInsight.com — Fri, 07 Jan 2011 23:08:24 GMT

BOPH is delivering recurring revenue and earnings growth in
the rapidly expanding TCM segment of the emerging Chinese
healthcare market. The Company benefits from key protection
status for its core products and very positive preliminary results
on the launching of 5 new products, which bring the total
number of manufactured medicines to 15 prescription and over
the counter products. The Company has a strategy to capitalize
on growth opportunities in urban and rural markets and seems
to be well positioned to monetize these opportunities.

Bohai Pharmaceuticals Group, Inc. (BOPH) - Murphy Analytics

InvestorsInsight.com — Tue, 21 Sep 2010 21:36:20 GMT

Based in the city of Yantai, Shandong Province, China, Bohai Pharmaceuticals Group, Inc. is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on traditional Chinese medicine in China. Bohai's medicines address common health problems such as rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. Bohai's products are sold either by prescription through hospitals or Over the Counter through local pharmacies, hospitals and retail drug store chains. Bohai has approximately 600 employees, including approximately 300 sales representatives, operating from 20 offices throughout China. Bohai's lead products, Tongbi Capsules and Tablets and Lung Nourishing Cream, are eligible for reimbursement under China's National Medical Insurance Program.

China Shuangji Cement (CSGJ - OTC:BB) - Updated Research Report by Harbinger Research

InvestorsInsight.com — Tue, 14 Sep 2010 04:01:38 GMT

China Shuangji Cement is a growing, high-quality provider of Portland cement that has experienced flat sales recently due only to an extraordinary event: the forced relocation of one of its major production facilities. However, this does not affect our belief that the Company has high-quality products that are and will continue to be in high demand in the markets in which it operates. Furthermore, we believe that the "clean up" policies of the PRC government strongly favor the Company, apart from its one older Hainan facility, given its status as one of the larger and more technologically advanced producers that is likely to benefit from industry consolidation. Quite simply, we find the combination of CSGJ's strong results, low valuation, and favorable industry fundamentals to be very compelling. We therefore rate the shares of CSGJ a Buy, and set our 12-month price target at US$1.00 per share, representing just 4x our 2011 EPS estimate of 0.248.

Sinobiopharma (SNBP - OTC:BB)

InvestorsInsight.com — Thu, 08 Jul 2010 14:26:10 GMT

Sinobiopharma is a profitable, rapidly-growing specialty pharmaceutical manufacturer. The Company introduced KuTai, a muscle relaxant and First to Market drug in 2006 and has already captured 70% of the market for muscle relaxant of Cisatracurium in the PRC. The Company introduced YiTai, a hypertension treatment and second First to Market drug in October of last year and targets YiTai sales reaching peak levels of $20 million within three years. Sinobiopharma's business plan leverages the advantages of its proprietary technology for low cost API synthesis and improved drug formulations. Initially, Sinobipharma plans to focus on developing additional high margin, First to Market drugs in the PRC. Longer-term the Company plans to commence exporting low cost API to overseas markets and developing new drugs based on Traditional Chinese Medicines. We believe that the Company will deliver robust revenue and profit growth from YiTai and other new products. With growth rates likely to exceed those of the overall PRC pharmaceutical market, we look for the multiple on SNBP shares to expand from current "fair value" levels of only 4.5x our FY 2011 EPS estimate of $0.05 to a range of 12x – 14x forward earnings. We thus rate SNBP shares a Strong Buy, and set our 12-month price target at $0.65 per share.

DecisionPoint Systems (DNPI - OTC:BB)

InvestorsInsight.com — Wed, 09 Jun 2010 15:03:56 GMT

DecisionPoint Systems is a national leader in a very high growth industry - corporate mobile technology. The Company has solid, serially-successful leaders and a sound business plan. It has demonstrated it can land major accounts and has amassed a solid growth record over several years. We believe that the shares are currently depressed from previous levels due to a misunderstanding of the Company’s recent lack of revenue and EPS growth, which we attribute to now-reversing negative macro economic factors. We have therefore establish our 12-month price target for DNPI shares at $1.04, and see considerable upside to this price target over the next few quarters. We therefore rate the shares of DNPI Strong Buy.

China Baicaotang Medicine (CNBI - OTC:BB)

InvestorsInsight.com — Tue, 11 May 2010 13:28:34 GMT

China Baicaotang is already a successful, well-established pharmaceutical manufacturer, wholesaler, and retailer in the Guangxi province of China. The Company has recently gained access to significant growth capital, and is expected to gain even more in the near future, allowing it to invest in next-generation infrastructure and more aggressive expansion across all of its business lines. We believe that as this process progresses, the Company will strengthen its competitive advantages in the Guangxi markets, and will likely experience rising gross and net margins. This will almost certainly lead to multiple expansion from current "fair value" levels of 10x - 15x forward earnings, and the Company currently trades at just 4.9x our 2010 EPS estimate of $0.67. Therefore we rate the shares of CNBI a Strong Buy, and set our 12-month price target at $6.70 per share.

Orient Paper, Inc. (ONP - AMEX) - Coverage Initiation Report by Harbinger Research

InvestorsInsight.com — Thu, 22 Apr 2010 03:17:04 GMT

Orient Paper is a regional leader in a very strong industry - Chinese paper manufacturing. In addition to strong and rapidly growing domestic demand for paper in China, China's status as the global manufacturing leader means that it also has very high export-related paper demand. Orient Paper has already demonstrated its ability to capitalize on this strong demand, having become the largest paper manufacturer in the Beijing metropolitan area, and we believe that it is likely to experience even more success in the coming one to two years. The Company is well-managed by an industry veteran and strong leadership team, and has what we believe to be a sound growth and expansion strategy. The company has a clean balance sheet and capital structure and has demonstrated operational excellence. As a result, we believe that the shares of Orient Paper are significantly undervalued at currently levels, and should be seriously considered for investment by growth-oriented risktolerant investors. We rate the share of ONP a Strong Buy and set our 12-month price target to $16.60 per share.

Cereplast, Inc. (CERP - NasdaqCM) - Coverage Initiation Report by Harbinger Research

InvestorsInsight.com — Tue, 20 Apr 2010 21:15:22 GMT

Cereplast has innovative and unique technology in the field of bioplastics. It has a solid portfolio of intellectual property and has been making solid inroads with potential customers (e.g. Georgia Pacific, Wal-Mart, Target). Overall, we have confidence in both its technology and management team, and believe that it operates in an industry poised for hyper-growth. Although it is too early to be certain of Cereplast's eventual success, we believe that is shares currently represent an excellent risk-reward trade off for risk-tolerant investors. Therefore, we are initiating coverage of Cereplast with a rating of Strong Speculative Buy. As 2010 progresses, Cereplast's success at raising additional capital will probably determine its eventual attractiveness, and we will view any progress in this regard as an extremely positive sign.